Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, neurofibrillary tangles (NFT), synaptic loss and reactive gliosis. Current diagnosis of AD is made by clinical, neuropsychologic, and neuroimaging assessments. Routine structural neuroimaging evaluation with computed tomography (CT) and magnetic resonance imaging (MRI) is based on nonspecific features such as atrophy, a late feature in the progression of the disease, hence the crucial importance of developing new approaches for early and specific recognition at the prodromal stages of AD. Functional neuroimaging techniques such as functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET) and single photon emission computed tomography (SPECT), possibly in conjuction with other related Aβ biomarkers in plasma and CSF, could prove to be valuable in the differential diagnosis of AD, as well as in assessing prognosis. With the advent of new therapeutic strategies aimed at reducing the Aβ amyloid burden in the brain, there is increasing interest in the development of MRI contrast agents and PET and SPECT radioligands that will permit the assessment of Aβ amyloid burden in vivo.
LarsonEBEdwardsJKO'MearaE: Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J Gerontol A Biol Sci Med Sci51: M313–M318, 1996.
6.
RasmussonDXBrandtJSteeleC: Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord10: 180–188, 1996.
7.
American Psychiatric Association DSM-IV: Diagnostic and statistical manual (Fourth Edition). DSM-IV: Diagnostic and statistical manual (Fourth Edition), Washington, DC: American Psychiatric Association1994.
8.
International Classification of Diseases, 10th edition (ICD-10): Classification of mental and behavioural disorders. Geneva, Switzerland: World Health Organization1992.
9.
McKhannGDrachmanDFolsteinM: Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology34: 939–944, 1984.
10.
PetersenRCStevensJCGanguliM: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56: 1133–1142, 2001.
11.
PetersenRC: Mild cognitive impairment: Transition between aging and Alzheimer's disease. Neurologia15: 93–101, 2000.
PetersenRCSmithGEIvnikRJ: Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA273: 1274–1278, 1995.
14.
MastersCL: Neuropathology of Alzheimer's Disease, in Dementia (3rd Edition), BurnsAO'BrienJ, and AmesD, Editors Hodder Arnold, London2005: 393–407.
15.
MastersCLBeyreutherK: The neuropathology of Alzheimer's disease in the year 2005, in Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, BealMFLangAE, and LudolphAC, Editors Cambridge University Press: Cambridge2005: 433–440.
16.
JellingerK: Morphology of Alzheimer disease and related disorders, in Alzheimer disease: Epidemiology, neuropathology, neurochemistry, and clinics, MaurerKRiedererP, and BeckmannH, Editors Springer-Verlag1990: 61–77.
17.
MichaelisMLDobrowskyRTLiG: Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci19: 289–293, 2002.
18.
JellingerKABancherC: Neuropathology of Alzheimer's disease: A critical update. J Neural TransmSuppl54: 77–95, 1998.
19.
PerlDP: Neuropathology of Alzheimer's disease and related disorders. Neurol Clin18: 847–864, 2000.
GeulaCWuCKSaroffD: Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med4: 827–831, 1998.
22.
LuMKosikKS: Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell12: 171–184, 2001.
23.
YanknerBADuffyLKKirschnerDA: Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science250: 279–282, 1990.
24.
LovestoneSReynoldsCH: The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes. Neuroscience78: 309–324, 1997.
25.
FrankRAGalaskoDHampelH: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging24: 521–536, 2003.
26.
GeulaC: The early diagnosis of Alzheimer's disease, in Pathological diagnosis of Alzheimer's disease, ScintoLFM and O'NeillK.R.D., Editors. Humana: Totowa, NJ2000: 65–82.
27.
MastersCLSimmsGWeinmanNA: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA82: 4245–4249, 1985.
28.
CappaiRWhiteAR: Amyloid beta. Int J Biochem Cell Biol31: 885–889, 1999.
29.
HaassCKooEHMellonA: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature357: 500–503, 1992.
30.
SeubertPVigo-PelfreyCEschF: Isolation and quantification of soluble Alzhe imer's beta-peptide from biological fluids. Nature359: 325–327, 1992.
31.
ShojiMGoldeTEGhisoJ: Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science258: 126–129, 1992.
32.
GlennerGGWongCW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun120: 885–890, 1984.
33.
HarperJDLansburyPTJr: Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem66: 385–407, 1997.
34.
SotoCCastanoEMFrangioneB: The alphahelical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem270: 3063–3067, 1995.
35.
InoueSKuroiwaMTanR: A high resolution ultrastructural comparison of isolated and in situ murine AA amyloid fibrils. Amyloid5: 99–110, 1998.
36.
CohenASShirahamaTSkinnerM: Electron microscopy of amyloid, in Electron Microscopy of Proteins, HarrisJR, Editor. Academic Press, London1982: 165–205.
37.
SelkoeDJ: Alzheimer's disease is a synaptic failure. Science298: 789–791, 2002.
38.
SelkoeDJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci924: 17–25, 2000.
39.
SelkoeDJ, The genetics and molecular pathology of Alzheimer's disease: Roles of amyloid and the presenilins. Neurol Clin18: 903–922, 2000.
MastersCLBeyreutherK: Molecular neuropathology of Alzheimer's disease. Arzneimittelforschung45: 410–412, 1995.
42.
BartusRTEmerichDF: Cholinergic markers in Alzheimer disease. Jama282: 2208–2209, 1999.
43.
HardyJSelkoeDJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science297: 353–356, 2002.
44.
RitchieCWMcLeanCBeyreutherK: Role of Abeta amyloid in the pathogenesis of Alzheimer's Disease, in Dementia (3rd Edition), BurnsAO'BrienJ, and AmesD, Editors Hodder Arnold: London2005: 426–435.
WestermarkPBensonMDBuxbaumJN: Amyloid fibril protein nomenclature 2002. Amyloid9: 197–200, 2002.
47.
StevensFJKisilevskyR: Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci57: 441–449, 2000.
48.
PerryEKTomlinsonBEBlessedG: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J2: 1457–1459, 1978.
49.
BlessedGTomlinsonBERothM: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry114: 797–811, 1968.
50.
YamaguchiHHiraiSMorimatsuM: Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (Berl)77: 113–119, 1988.
51.
SunderlandTLinkerGMirzaN: Decreased beta-amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama289: 2094–2103, 2003.
52.
McLeanCAChernyRAFraserFW: Soluble pool of Aß amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol46: 860–866, 1999.
53.
MegaMSChuTMazziottaJC: Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport10: 2911–2917, 1999.
54.
GreenbergSMRebeckGWVonsattelJP: Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol38: 254–259, 1995.
55.
McLeanCABeyreutherKMastersCL: Amyloid Abeta levels in Alzheimer's disease. A diagnostic tool and the key to understanding the natural history of Abeta?J Alzheimers Dis3: 305–312, 2001.
56.
NaslundJHaroutunianVMohsR: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama283: 1571–1577, 2000.
57.
LueLFKuoYMRoherAE: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol155: 853–862, 1999.
58.
WangJDicksonDWTrojanowskiJQ: The levels of soluble versus insoluble brain Aß distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol158: 328–337, 1999.
59.
SelkoeDJ: The molecular pathology of Alzheimer's disease. Neuron6: 487–498, 1991.
60.
HardyJAHigginsGA: Alzheimer's disease: The amyloid cascade hypothesis. Science256: 184–185, 1992.
61.
CheclerFVincentB: Alzheimer's and prion diseases: Distinct pathologies, common proteolytic denominators. Trends Neurosci25: 616–620, 2002.
62.
RobinsonSRBishopGM: The search for an amyloid solution. Science298: 962–964, 2002.
63.
HardyJ: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci20: 154–159, 1997.
SelkoeDJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature399: 23–31, 1999.
66.
St George-HyslopPH: Genetic factors in the genesis of Alzheimer's disease. Ann NY Acad Sci924: 1–7, 2000.
67.
CitronMOltersdorfTHaassC: Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature360: 672–674, 1992.
68.
CaiXDGoldeTEYounkinSG: Release of excess zamyloid beta protein from a mutant amyloid beta protein precursor. Science259: 514–516, 1993.
69.
SuzukiNCheungTTCaiXD: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science264: 1336–1340, 1994.
70.
CitronMVigo-PelfreyCTeplowDB: Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA91: 11993–11997, 1994.
71.
GoateAChartier-HarlinMCMullanM: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature349: 704–706, 1991.
72.
Rovelet-LecruxAHannequinDRauxG: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet38: 24–26, 2006.
73.
MiklossyJTaddeiKSuvaD: Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol Aging24: 655–662, 2003.
74.
RogaevEISherringtonRRogaevaEA: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature376: 775–778, 1995.
75.
SherringtonRRogaevEILiangY: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature375: 754–760, 1995.
76.
ScheunerDEckmanCJensenM: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med2: 864–870, 1996.
77.
CitronMWestawayDXiaW: Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med3: 67–72, 1997.
78.
DuffKEckmanCZehrC: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature383: 710–713, 1996.
79.
Levy-LahadEWascoWPoorkajP: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science269: 973–977, 1995.
80.
ThinakaranGTeplowDBSimanR: Metabolism of the “Swedish” amyloid precursor protein variant in neuro 2a (N2a) cells. Evidence that cleavage at the “beta-secretase” site occurs in the golgi apparatus. J Biol Chem271: 9390–9397, 1996.
81.
CorderEHSaundersAMStrittmatterWJ: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science261: 921–923, 1993.
82.
PoirierJDavignonJBouthillierD: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet342: 697–699, 1993.
83.
StrittmatterWJSaundersAMSchmechelD: Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA90: 1977–1981, 1993.
84.
BorcheltDRThinakaranGEckmanCB: Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron17: 1005–1013, 1996.
85.
PolvikoskiTSulkavaRHaltiaM: Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med333: 1242–1247, 1995.
86.
SchmechelDESaundersAMStrittmatterWJ: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U SA90: 9649–9653, 1993.
87.
RebeckGWReiterJSStricklandDK: Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron11: 575–580, 1993.
88.
HymanBTWestHLRebeckGW: Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA92: 3586–3590, 1995.
89.
MehtaNDRefoloLMEckmanC: Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol43: 256–258, 1998.
90.
SkovronskyDMDomsRWLeeVM: Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol141: 1031–1039, 1998.
91.
BushAI: The metallobiology of Alzheimer's disease. Trends Neurosci26: 207–214, 2003.
92.
HaassCSchlossmacherMGHungAY: Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature359: 322–325, 1992.
93.
HarkanyTHortobagyiTSasvariM: Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: Relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry23: 963–1008, 1999.
94.
HarkanyTAbrahamIKonyaC: Mechanisms of beta-amyloid neurotoxicity: Perspectives of pharmacotherapy. Rev Neurosci11: 329–382, 2000.
95.
ReiterRJ: Oxidative processes and antioxidative defense mechanisms in the aging brain. Faseb J9: 526–533, 1995.
96.
BushAI: Metals and neuroscience. Curr Opin Chem Biol4: 184–191, 2000.
97.
HuangXMoirRDTanziRE: Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci1012: 153–163, 2004.
98.
HuangXCuajungcoMPAtwoodCS: Alzheimer's disease, beta-amyloid protein and zinc. J Nutr130: 1488S–1492S, 2000.
99.
AtwoodCSHuangXMoirRD: Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst36: 309–364, 1999.
100.
BarnhamKJMastersCLBushAI: Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov3: 205–214, 2004.
101.
TomidokoroYIshiguroKHarigayaY: Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett299: 169–172, 2001.
102.
ZhengWHBastianettoSMennickenF: Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience115: 201–211, 2002.
DrouetBPincon-RaymondMChambazJ: Molecular basis of Alzheimer's disease. Cell Mol Life Sci57: 705–715, 2000.
105.
VajdaFJ: Neuroprotection and neurodegenerative disease. J Clin Neurosci9: 4–8, 2002.
106.
SaezTEPeharMVargasM: Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo18: 275–280, 2004.
107.
RoherAEChaneyMOKuoYM: Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem271: 20631–20635, 1996.
108.
WalshDMKlyubinIFadeevaJV: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature416: 535–539, 2002.
109.
HarperJDWongSSLieberCM: Assembly of A beta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry38: 8972–8980, 1999.
110.
PikeCJBurdickDWalencewiczAJ: Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci13: 1676–1687, 1993.
111.
LorenzoAYanknerBA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA91: 12243–12247, 1994.
112.
CurtainCCAliFVolitakisI: Alzheimer's disease amyloid-ß binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem276: 20466–20473, 2001.
113.
BushAIGoldsteinLE: Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: Focus on Alzheimer's disease and age-related cataracts. Novartis Found. Symp235: 26–43, 2001.
114.
CuajungcoMPGoldsteinLENunomuraA: Evidence that the ß-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aß by zinc. J. Biol. Chem275: 19439–19442, 2000.
115.
LambertMPBarlowAKChromyBA: Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA95: 6448–6453, 1998.
116.
HartleyDMWalshDMYeCP: Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci19: 8876–8884, 1999.
117.
HsiaAYMasliahEMcConlogueL: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA96: 3228–3233, 1999.
118.
MuckeLMasliahEYuGQ: High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci20: 4050–4058, 2000.
119.
SelkoeDJ: The early diagnosis of Alzheimer's disease., in The pathophysiology of Alzheimer's disease, ScintoLFM and DaffnerKR, Editors. Humana: Totowa, NJ2000: 83–104.
120.
BarrowCJ: Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease. Drug News Perspect15: 102–109, 2002.
121.
AuldDSKornecookTJBastianettoS: Alzheimer's disease and the basal forebrain cholinergic system: Relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol68: 209–245, 2002.
122.
BowenDMPalmerAMFrancesPT: Classical neurotransmitters in Alzheimer's disease, in Aging and the Brain, TerryRD, Editor. Raven Press: New York1988: 115–128.
123.
EmilienGBeyreutherKMastersCL: Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol57: 454–459, 2000.
124.
MobiusHJ: Memantine: Update on the current evidence. Int J Geriatr Psychiatry18: 47–54, 2003.
125.
WinbladBJelicV: Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry18: S41–46, 2003.
126.
RogawskiMAWenkGL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9: 275–308, 2003.
127.
ReisbergBDoodyRStofflerA: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med348: 1333–1341, 2003.
128.
MoosmannBBehlC: Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs11: 1407–1435, 2002.
129.
SanoMErnestoCThomasRG: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med336: 1216–1222, 1997.
130.
BanoSPariharMS: Reduction of lipid peroxidation in different brain regions by a combination of alpha-tocopherol and ascorbic acid. J Neural Transm104: 1277–1286, 1997.
131.
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med328: 176–183, 1993.
132.
SpinaMBSquintoSPMillerJ: Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J Neurochem59: 99–106, 1992.
133.
PrasadKNHovlandARColeWC: Multiple antioxidants in the prevention and treatment of Alzheimer disease: Analysis of biologic rationale. Clin Neuropharmacol23: 2–13, 2000.
134.
PariharMSHemnaniT: Experimental excitotoxicity provokes oxidative damage in mice brain and attenuation by extract of Asparagus racemosus. J Neural Transm111: 1–12, 2004.
BeyerRE: An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol70: 390–403, 1992.
137.
HemmerW and WallimannT, Functional aspects of creatine kinase in brain. Dev Neurosci15: 249–260, 1993.
138.
ByrneE: Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders?J Clin Neurosci9: 497–501, 2002.
139.
Mendoza-RamirezJLBeltran-ParrazalLVerdugo-DiazL: Delay in manifestations of aging by grafting NGF cultured chromaffin cells in adulthood. Neurobiol Aging16: 907–916, 1995.
140.
BehlCHolsboerF: The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci20: 441–444, 1999.
CutlerNRSramekJJ: Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry25: 27–57, 2001.
150.
ZimmermannMGardoniFMarcelloE: Ace-tylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem90: 1489–1499, 2004.
151.
CaccamoAOddoSBillingsLM: M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron, 49: 671–682, 2006.
152.
HaassCDe StrooperB: The presenilins in Alzheimer's disease—proteolysis holds the key. Science286: 916–919, 1999.
153.
WongGTManfraDPouletFM: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem279: 12876–12882, 2004.
154.
KingGDCherianKTurnerRS: X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. J Neurochem, 88(4): P. 971–982, 2004.
155.
LanzTAHosleyJDAdamsWJ: Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-Lalaninamide (LY-411575). J Pharmacol Exp Ther309: 49–55, 2004.
156.
KornilovaAYDasCWolfeMS: Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications. J Biol Chem278: 16470–16473, 2003.
157.
LanzTAHimesCSPallanteG: The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther305: 864–871, 2003.
158.
TakahashiYHayashiITominariY: Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem278: 18664–18670, 2003.
159.
WolfeMS: Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov1: 859–866, 2002.
160.
SchenkD: Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci3: 824–828, 2002.
161.
McLaurinJCecalRKiersteadME: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat Med8: 1263–1269, 2002.
162.
HockCKonietzkoUPapassotiropoulosA: Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med8: 1270–1275, 2002.
163.
SchenkDBarbourRDunnW: Immunization with amyloid-ß attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400: 173–177, 1999.
164.
JanusC: Vaccines for Alzheimer's disease: How close are we?CNS Drugs17: 457–474, 2003.
165.
ChernyRAAtwoodCSXilinasME: Treatment with a copper-zinc chelator markedly and rapidly inhibits ß-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron30: 665–676, 2001.
166.
WeinerHLLemereCAMaronR: Nasal administration of amyloid-ß peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol48: 567–579, 2000.
167.
JanusCPearsonJMcLaurinJ: Aß-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature408: 979–982, 2000.
168.
BardFCannonCBarbourR: Peripherally administered antibodies against amyloid ß peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med6: 916–919, 2000.
169.
DeMattosRBBalesKRCumminsDJ: Peripheral anti-Aß antibody alters CNS and plasma Aß clearance and decreases brain Aß burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA98: 8850–8855, 2001.
170.
WilcockDMDiCarloGHendersonD: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci23: 3745–3751, 2003.
171.
RobinsonSRBishopGMLeeHG: Lessons from the AN 1792 Alzheimer vaccine: Lest we forget. Neurobiol Aging25: 609–615, 2004.
172.
BroytmanOMalterJS: Anti-Abeta: The good, the bad, and the unforeseen. J Neurosci Res75: 301–306, 2004.
173.
RobinsonSRBishopGMMunchG: Alzheimer vaccine: Amyloid-beta on trial. Bioessays25: 283–288, 2003.
174.
MunchGRobinsonSR: Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J Neural Transm109: 1081–1087, 2002.
175.
RogersJWebsterSLueLF: Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging17: 681–686, 1996.
176.
WeggenSEriksenJLDasP: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature414: 212–216, 2001.
177.
BeherDClarkeEEWrigleyJD: Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma -secretase at a novel site-evidence for an allosteric mechanism. J Biol Chem2004.
178.
LimGPYangFChuT: Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging22: 983–991, 2001.
179.
JantzenPTConnorKEDiCarloG: Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci22: 2246–2254, 2002.
180.
RefoloLMPappollaMALaFrancoisJ: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis8: 890–899, 2001.
181.
WolozinBKellmanWRuosseauP: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol57: 1439–1443, 2000.
182.
JickHZornbergGLJickSS: Statins and the risk of dementia. Lancet356: 1627–1631, 2000.
183.
SparksDLKuoYMRoherA: Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci903: 335–344, 2000.
184.
RefoloLMMalesterBLaFrancoisJ: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis7: 321–331, 2000.
185.
FassbenderKSimonsMBergmannC: Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA98: 5856–5861, 2001.
HuangXAtwoodCSHartshornMA: The Aß peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry38: 7609–7616, 1999.
190.
HuangXCuajungcoMPAtwoodCS: Cu(II) potentiation of Alzheimer Aß neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem274: 37111–37116, 1999.
191.
BushAIPettingellWHMulthaupG: Rapid induction of Alzheimer Aß amyloid formation by zinc. Science265: 1464–1467, 1994.
192.
LovellMARobertsonJDTeesdaleWJ: Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci.158: 47–52, 1998.
193.
BushAI: Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging23: 1031–1038, 2002.
194.
PadmanabhanG: In. KlaussE: Clioquinol. In Analytical Profiles of Drug Substances. In Analytical Profiles of Drug Substances, Academic Press: 57–90, 1989.
195.
RitchieCWBushAIMackinnonA: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol60: 1685–1691, 2003.
196.
JobstKASmithADSzatmariM: Detection in life of confirmed Alzheimer's idsease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet340: 1179–1183, 1992.
197.
ScheltensPH: Structural neuroimaging of Alzheimer's disease and other dementias. Aging13: 203–209, 2001.
198.
O'BrienJTMetcalfeSSwannA: Medial temporal lobe width on CT scanning in Alzheimer's disease; comparison with vascular dementia, depression and dementia with Lewy bodies. Dement. Geriatr. Cogn Disord11: 114–118, 2000.
199.
JuottonenKLaaksoMPInsaustiR: Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging19: 15–22, 1998.
200.
ThompsonPMHayashiKMDe ZubicarayGI: Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage22: 1754–1766, 2004.
201.
DuATSchuffNAmendD: Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry71(4): 441–447, 2001.
202.
WolfHJelicVGertzHJ: A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol ScandSuppl179: 52–76, 2003.
203.
de LeonMJDeSantiSZinkowskiR: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging27: 394–401, 2006.
204.
BarberRMcKeithIGBallardC: A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: Magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord12: 198–205, 2001.
205.
ChetelatGBaronJC: Early diagnosis of Alzheimer's disease; contribution of structural neuroimaging. Neuroimage18: 525–541, 2003.
206.
ScheltensPFoxNBarkhofF: Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion. Lancet Neurol1: 13–21, 2002.
207.
KillianyRJGomez-IslaTMossM: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol47: 430–439, 2000.
208.
KillianyRJHymanBTGomez-IslaT: MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology58: 1188–1196, 2002.
209.
PetrellaJRColemanREDoraiswamyPM: Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology226: 315–336, 2003.
210.
RapoportSI: Hydrogen magnetic resonance spectroscopy in Alzheimer's disease. Lancet Neurol1: 82, 2002.
211.
SchuffNCapizzanoAADuAT: Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology58: 928–935, 2002.
212.
XuYJackCRJO'BrienPC: Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology54: 1760–1767, 2000.
213.
de LeonMJConvitADeSantiS: Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int Psychogeriatr9: 183–190, 247–152, 1997.
214.
De Toledo-MorrellLGoncharovaIDickersonB: From healthy aging to early Alzheimer's disease: In vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci911: 240–253, 2000.
215.
BobinskiMde LeonMJConvitA: MRI of entorhinal cortex in mild Alzheimer's disease. Lancet353: 38–40, 1999.
216.
DickersonBCGoncharovaISullivanMP: MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging22: 747–754, 2001.
217.
SilvermanDH and PhelpsME: Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: Normal development, aging, dementia, and stroke. Mol Genet Metab74: 128–138, 2001.
218.
VillemagneVLRoweCCMacfarlaneS: Imaginem Oblivionis: The prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci12: 221–230, 2005.
219.
CourtneySMUngerleiderLGKeilK: Transient and sustained activity in a distributed neural system for human working memory. Nature386: 608–611, 1997.
220.
HarrisGJLewisRFSatlinA: Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: A promising alternative to nuclear medicine. Am J Neuroradiol19: 1727–1732, 1998.
221.
BozzaoAFlorisRBavieraME: Diffusion and perfusion MR imaging in cases of Alzheimer's disease: Correlations with cortical atrophy and lesion load. Am J Neuroradiol22: 1030–1036, 2001.
222.
DoraiswamyPMChenJGCharlesHC: Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease. CNS Drugs14: 457–472, 2000.
223.
JessenFBlockWTraberF: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology55: 684–688, 2000.
224.
LongoRGiorginiAMagnaldiS: Alzheimer's disease histologically proven studied by MRI and MRS: Two cases. Magn Reson Imaging11: 1209–1215, 1993.
225.
MillerEKLiLDesimoneR: Activity of neurons in anterior inferior temporal cortex during a short-term memory task. J Neurosci13: 1460–1478, 1993.
226.
FrederickBBSatlinAYurgelun-ToddDA: In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry42: 147–150, 1997.
227.
KlunkWEPanchalingamKMoossyJ: Acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology42: 1578–1585, 1992.
228.
MohanakrishnanPFowlerAHVonsattelJP: An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res102: 503–510, 1995.
229.
SatlinABodickNOffenWW: Brain proton magnetic resonance spectroscopy (H-MRS) in Alzheimer's disease: Changes after treatment with xanomeline, an M1 selective cholinergic agonist. AmJ Psychiatry154: 1459–1461, 1997.
KantarciKJackCRXuYC: Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology219: 101–107, 2001.
232.
RoseSEChenFChalkJB: Loss of connectivity in Alzheimer's disease: An evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry69: 528–530, 2000.
233.
PhelpsME: PET: The merging of biology and imaging into molecular imaging. J Nucl Med41: 661–681, 2000.
234.
CamargoEE: Brain SPECT in neurology and psychiatry. J Nucl Med42: 611–623, 2001.
235.
Van HeertumRLTikofskyRS: Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med33: 77–85, 2003.
236.
SalmonESadzotBMaquetP: Differential diagnosis of Alzheimer's disease with PET. J Nucl Med35: 391–398, 1994.
237.
KnopmanDSDeKoskySTCummingsJL: Practice parameter: Diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56: 1143–1153, 2001.
238.
DoodyRSStevensJCBeckC: Practice parameter: Management of dementia (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56: 1154–1166, 2001.
239.
SilvermanDHChangCYCummingsJL: Prognostic value of regional brain metabolism in evaluation of dementia. J Nucl Med40: 71, 1999.
240.
ChangCYSilvermanDH: Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev Mol Diagn4: 63–69, 2004.
241.
SilvermanDHGambhirSSHuangHW: Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J Nucl Med43: 253–266, 2002.
242.
SilvermanDHSmallGWChangCY: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA286: 2120–2127, 2001.
243.
DevanandDPJacobsDMTangMX: The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry54: 257–263, 1997.
244.
ColemanRE: Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am15: 837–846, x, 2005.
245.
SilvermanDHCummingsJLSmallG: Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol4: 283–2893, 2002.
246.
KennedyAMFrackowiakRSNewmanSK: Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett186: 17–20, 1995.
247.
SmallGWMazziottaJCCollinsMT: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA273: 942–947, 1995.
248.
DrzezgaALautenschlagerNSiebnerH: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging30: 1104–1113, 2003.
249.
TalbotPRLloydJJSnowdenJS: A clinical role for 99mTc- HMPAO SPECT in the investigation of dementia?J Neurol Neurosurg Psychiatry64: 306–313, 1998.
250.
CharpentierPLavenuIDefebvreL: Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry69: 661–663, 2000.
251.
SjogrenMGustafsonLWikkelsoC: Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBFSPET ratio. Dement Geriatr Cogn Disord11: 275–285, 2000.
252.
IshiiKYamajiSKitagakiH: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology53: 413–416, 1999.
253.
LobotesisKFenwickJDPhippsA: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology56: 643–649, 2001.
254.
JobstKABarnetsonLPShepstoneBJ: Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, x-ray CT, and Apo E4 in medial temporal lobe dementias: Oxford Project to Investigate Memory and Aging. Int Psychogeriatr10: 271–302, 1998.
255.
McKelveyRBergmanHSternJ: Lack of prognostic significance of SPECT abnormalities in nondemented elderly subjects with memory loss. Can J Neurol Sci26: 23–28, 1999.
256.
JohnsonKAJonesKHolmanBL: Preclinical prediction of Alzheimer's disease using SPECT. Neurology50: 1563–1571, 1998.
257.
JohnsonKALoperaFJonesK: Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology56: 1545–1551, 2001.
258.
VillemagneVLMusachioJLScheffelU: Nicotine and Related Compounds as PET and SPECT Ligands. In Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, John Wiley & Sons. New York: 235–250, 1998.
259.
NordbergAHartvigPLiljaA: Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography. Acta RadiolSuppl376: 165–166, 1991.
260.
VolkowNDDingYSFowlerJS: Imaging brain cholinergic activity with positron emission tomography: Its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry49: 211–220, 2001.
261.
SihverWLangstromBNordbergA: Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol ScandSuppl176: 27–33, 2000.
262.
VillemagneVLHortiAScheffelU: Imaging Nicotinic Acetylcholine Receptors with PET and [F-18]-FPH, a [F-18]-Labeled Analog of Epibatidine. J Nucl Med38: 1737–1741, 1997.
263.
MusachioJLVillemagneVLScheffelU: [125/123I]IPH: A Radioiodinated Analog of Epibatidine for In Vivo Studies of Nicotinic Acetylcholine Receptors. Synapse26: 392–399, 1997.
264.
MusachioJLVillemagneVLScheffelUA: Synthesis of an I-123 Analog of A-85380 and Preliminary SPECT Imaging of Nicotinic Receptors in Baboon. Nucl Med Biol26: 201–207, 1999.
265.
NordbergA: In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann N Y Acad Sc695: 27–33, 1993.
266.
NordbergA: Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res57: 215–224, 1993.
267.
NordbergAAmberlaKShigetaM: Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord12: 228–237, 1998.
268.
NordbergALundqvistHHartvigP: Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment. Dement Geriatr Cogn Disord8: 78–84, 1997.
269.
NordbergA: Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta Neurol ScandSuppl149: 62–65, 1993.
HiguchiMYanaiKOkamuraN: Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience99: 721–729, 2000.
272.
SmallGW: Neuroimaging as a diagnostic tool in dementia with Lewy bodies. Dement Geriatr Cogn Disord17: 25–31, 2004.
273.
WalkerZCostaDCWalkerRW: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry73: 134–140, 2002.
274.
KemppainenNRuottinenHNagrenK, PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology55: 205–209, 2000.
275.
KepeVBarrioJRHuangSC: Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA103: 702–707, 2006.
276.
VersijptJVan LaereKJDumontF: Imaging of the 5-HT2A system: Age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging24: 553–561, 2003.
277.
CohenRMAndreasonPJDoudetDJ: Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J Neurol Sci148: 171–180, 1997.
278.
BrownDRWyperDJOwensJ: 123Iodo-MK-801: A spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. J Psychiatr Res31: 605–619, 1997.
279.
PiggottMAOwensJO'BrienJ: Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat25: 161–173, 2003.
280.
VillemagneVLRoweCCMacfarlaneS: Imaginem Oblivionis: The prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci, in press 2004.
281.
SairHIDoraiswamyPMPetrellaJR: In vivo amyloid imaging in Alzheimer's disease. Neuroradiology46: 93–104, 2004.
282.
ZhangJYarowskyPGordonMN: Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med51: 452–457, 2004.
283.
BenvenisteHEinsteinGKimKR: Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA96: 14079–14084, 1999.
284.
HiguchiMIwataNMatsubaY: (19)F and (1)H MRI detection of amyloid beta plaques in vivo. Nat Neurosci8: 527–533, 2005.
285.
SatoKHiguchiMIwataN: Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem39: 573–578, 2004.
286.
OkamuraNSuemotoTFurumotoS: Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci25: 10857–10862, 2005.
287.
KungMPHouCZhuangZP: IMPY: An improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res Bull956: 202–210, 2002.
288.
OnoMWilsonANobregaJ: 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol, 30: 565–571, 2003.
289.
KungMPSkovronskyDMHouC: Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: Potential imaging agents in Alzheimer's patients. J Mol Neurosci20: 15–24, 2003.
290.
LinkCDJohnsonCJFonteV: Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging22: 217–226, 2001.
291.
KlunkWEBacskaiBJMathisCA: Imaging Aß plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropath Exp Neurol61: 797–805, 2002.
292.
ZhuangZPKungMPHouC: IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): A ligand for imaging amyloid plaques in the brain. Nucl Med Biol28: 887–894, 2001.
293.
LeeCWZhuangZPKungMP, Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: Probes for amyloid plaques in the brain. J Med Chem44: 2270–2275, 2001.
294.
KlunkWEWangYHuangGF, The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci23: 2086–2092, 2003.
295.
KlunkWEWangYHuangGF: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci69: 1471–1484, 2001.
296.
MathisCABacskaiBJKajdaszST: A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett12: 295–298, 2002.
297.
BacskaiBJHickeyGASkochJ: Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA100: 12462–12467, 2003.
298.
MathisCAHoltDPWangY: Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. J. Labelled Cpd. Radiopharm44: S26–S28, 2001.
299.
MathisCAWangYHoltDP: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem46: 2740–2754, 2003.
300.
KlunkWEEnglerHNordbergA: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol55: 306–319, 2004.
301.
SkovronskyDMZhangBKungMP: In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA97: 7609–7614, 2000.
302.
KungHFLeeCWZhuangZP: Novel stilbenes as probes for amyloid plaques. J Am Chem Soc123: 740–12741, 2001.
303.
ShimadzuHSuemotoTSuzukiM: A novel probe for imaging amyloid-b: Synthesis of F-18 labelled BF-108, an Acridine Orange analog. J Label Compd Radiopharm46: 765–772, 2003.
304.
ZhangWOyaSKungMP: F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol32: 799–809, 2005.
305.
KungMPHouCZhuangZP: Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res1025: 98–105, 2004.
306.
AgdeppaEDKepeVPetriA: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene) malononitrile. Neuroscience117: 723–730, 2003.
307.
AgdeppaEDKepeVLiuJ: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthyl-ethylidene derivatives as positron emission tomography imaging probes for ß-amyloid plaques in Alzheimer's disease. J Neurosci21: RC189, 2001.
308.
BarrioJRHuangSCColeG: PET imaging of tangles and plaques in Alzheimer disease with a highly lipophilic probe. J Labelled Compd Radiopharm42: S194–S195, 1999.
309.
Shoghi-JadidKSmallGWAgdeppaED: Localisation of neurofibrillary tangles and ß-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Ger Psychiatry10: 24–35, 2002.
310.
AgdeppaEDKepeVShoghi-JadidK: In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: A case study. J Nucl Med42: 65P, 2001.
311.
SmallGWAgdeppaEDKepeV: In vivo brain imaging of tangle burden in humans. J Mol Neurosci19: 323–327, 2002.
312.
LeeVM: Related Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging23: 1039–1042, 2002.
313.
MarshallJRStimsonERGhilardiJR: Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug Chem13: 276–284, 2002.
314.
FriedlandRPShiJLamannaJC: Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann N Y Acad Sci903: 123–128, 2000.
315.
GhilardiJRCattonMStimsonER: Intra-arterial infusion of [125I]A beta 1–40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport7: 2607–2611, 1996.
316.
KuriharaAPardridgeWM: Abeta(1–40) peptide radiopharmaceuticals for brain amyloid imaging: (111) In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug Chem11: 380–386, 2000.
317.
SaitoYBuciakJYangJ: Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1–40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci USA92: 10227–10231, 1995.
318.
MajochaRERenoJMFriedlandRP: Development of a monoclonal antibody specific for ß/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med33: 2184–2189, 1992.
319.
WalkerLCPriceDLVoytkoML: Labelling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol53: 377–383, 1994.
320.
ShiJPerryGBerridgeMS: Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med43: 1044–1051, 2002.
321.
WadghiriYZSigurdssonEMWisniewskiT: Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol299: 365–379, 2005.
322.
VanhoutteGDewachterIBorghgraefP: Non-invasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med53: 607–613, 2005.
323.
WadghiriYZSigurdssonEMSadowskiM: Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med50: 293–302, 2003.
324.
FalangolaMFLeeSPNixonRA: Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res30: 201–205, 2005.
325.
MathisCAKlunkWEPriceJC: Imaging technology for neurodegenerative diseases: Progress toward detection of specific pathologies. Arch Neurol62: 196–200, 2005.
326.
YeLMorgensternJLGeeAD: Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem280: 23599–23604, 2005.
327.
LockhartAYeLJuddDB: Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem280: 7677–7684, 2005.
328.
ToyamaHYeDIchiseM: PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging32: 593–600, 2005.
329.
KlunkWEEnglerHNordbergA: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol55: 306–319, 2004.
330.
VerhoeffNPWilsonAATakeshitaS: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry12: 584–595, 2004.
331.
PriceJCKlunkWELoprestiBJ: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab2005.
332.
BucknerRLSnyderAZShannonBJ: Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci25: 7709–7717, 2005.
333.
VillemagneVLAckermannUGongSJ: Abeta amyloid imaging in dementia with Lewy bodies and Alzheimer's disease with 11C-PIB PET. J Nucl Med46: 124P, 2005.
334.
PriceJLMorrisJC: Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol45: 358–368, 1999.
335.
HuletteCMWelsh-BohmerKAMurrayMG: Neuropathological and neuropsychological changes in “normal” aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol57: 1168–1174, 1998.
336.
MorrisJCPriceAL: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci17: 101–118, 2001.
